(Q39383777)

11 September 2017

title

Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study (English)

1 reference

11 September 2017

1 reference

coronary artery disease

1 reference

8

Kay-Tee Khaw

1 reference

11 September 2017

6

Nicholas J Wareham

1 reference

11 September 2017

5

John J P Kastelein

1 reference

11 September 2017

author name string

Brigitte M Sondermeijer

1

1 reference

11 September 2017

Jamal S Rana

2

1 reference

11 September 2017

Benoit J Arsenault

3

1 reference

11 September 2017

Prediman K Shah

4

1 reference

11 September 2017

S Matthijs Boekholdt

7

1 reference

11 September 2017

language of work or name

1 reference

17 July 2013

1 reference

European Journal of Clinical Investigation

11 September 2017

published in

1 reference

11 September 2017

volume

43

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

1009-1015

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

11 September 2017

cites work

1 reference

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database

21 January 2018

1 reference

How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.

21 January 2018

1 reference

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.

21 January 2018

1 reference

To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

21 January 2018

1 reference

Using apolipoprotein B to manage dyslipidemia

21 January 2018

1 reference

Are you targeting non-high-density lipoprotein cholesterol?

21 January 2018

1 reference

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently

21 January 2018

1 reference

Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk

21 January 2018

1 reference

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls

21 January 2018

1 reference

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk

21 January 2018

1 reference

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

21 January 2018

1 reference

Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?

21 January 2018

1 reference

Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ECI.12129

1 reference

11 September 2017

1 reference